Oct 29th Day 1

08:29

Opening Plenary Session

Panel discussion
08:40

Paradigm shift in vaccine funding capacity and collaborations for disease X and persistent epidemics

  • How are we incentivizing vaccine development?
  • How will these vaccines reach the LMICs and developing countries?
  • CEPI’s strategy and investment to advance medical countermeasures to emerging diseases
  • The potential of translational medicine and access for all
  • How to secure public funding to advance research and vaccine development
Panel discussion
09:25

Are we pandemic ready for influenza? How to close the gaps in our current strategy in preparedness

  • The importance of cross species consideration in influenza during pre-pandemic preparedness
  • What is our response mechanism in medical and non-medical interventions?
  • European wide actions to provide global health, sustainable policies, coverage and access – joint procurement
  • The role of industry in vaccine matching, manufacturing and antivirals
Laszlo Radvanyi
10:10

What will 2020 hold for immuno-oncology? A global landscape and overview of promising approaches

  • Emerging immuno-oncology targets and modalities
  • Exploring possible uses of artificial intelligence in oncology (patient stratification, predicting patient response to treatment, AI as a diagnostic tool etc)
  • Ensuring patient centricity in oncology clinical trials
  • Looking to the future: How can we go further to make precision medicine a reality for cancer patients?
10:40

Morning Networking Break

2 x Interactive Roundtables

11:40 to 12:25 (rotation one) and 12:25 to 13:10 (rotation two). If you have not filled out the survey please choose them on the sign-up sheets located outside of the exhibition hall/or ask registration for more information. Choose two x 45 min long roundtables for these interactive discussions with like-minded peers in:
11:40

Are PD-1 Antibodies transforming cancer therapy?

11:40

Biodefence: The role of vaccines in preventing outbreaks, through natural causes or biothreats

11:40

Challenges in trial design, implementation and safety assessment under clinical development

  • Challenges in Phase IV studies and register based impact research
  • Post-licensure safety studies using real world data
11:40

Development pathways for combining immune-based therapies in cancer: leveraging disease biology, complex biomarkers, regulatory approval and pathways to adoption

11:40

Do we understand the biology behind cold and hot tumours, which is needed for successful treatment and what is the role for biomarkers?

11:40

Establishing a One Health approach to combat emerging zoonotic & transboundary diseases

11:40

Further follow up on: Are we pandemic ready for influenza? How to close the gaps in our current strategy in preparedness

11:40

Further follow up on: Paradigm shift in vaccine funding capacity and collaborations for disease X and persistent epidemics

11:40

Intradermal delivery of therapeutic vaccines – benefits and challenges

Kirsty Gapp, Head of Global Transdermal Business Development & MTS strategy, 3M
11:40

Practical use of systems biology in vaccinology

11:40

Strategies for selecting the right immuno-oncology tumour model

11:40

Strengthening human & animal public health systems at their interface to prevent AMR: Spanish National Action Plan against Antimicrobial Resistance

11:40

Unique Operational Challenges for Vaccines Clinical Development.

11:40

Virtual trials—do they have a role in vaccine studies

13:10

Networking Lunch & Poster Sessions

14:39

Cancer Vaccines

14:39

Influenza Vaccines

14:39

New Platform & Delivery Technologies

14:39

One Health

14:39

Vector Borne Diseases

14:39

What are the AMR targets for vaccines?

AMR
15:15

Harmonising priorities in Europe: Role of public health, government strategies and industry to halting the AMR crisis – do we have a consistent message?

Insight and progress from international healthcare agencies; How can regulatory and access policies can be used to strengthen utilization of vaccines in our international action plans to address AMR?
Bryan Deane, New Medicines, ABPI
Emerging Diseases
16:15

A single-dose live-attenuated Zika vaccine

16:45

Afternoon Networking Break

Companion Animals
17:15

Building international capacity to tackle AMR more efficiently – is this in line with Europe?

Stewardship & social behaviour change in Europe – do we have measurable push & pull outcomes?
Immuno-oncology
17:15

Developing personalized neoantigen cancer vaccines to target solid tumors

- Inducing a unique CD8-dominated T cell response- Clinical updates on phase I/IIa VB10.NEO vaccine trial
Emerging Diseases
17:15

New immune-data and correlates analysis on our Ebola vaccine

Jerry Sadoff, Senior Advisor, Janssen
18:15

Chair closing remarks of day one followed by Drinks Reception host by Enesi Pharma

last published: 17/Oct/19 16:45 GMT